GFAP and Alzheimer disease: Longitudinal follow-up occurred annually for up to ∼10 years, with clinical conversion determined according to NIA-AA criteria.<h4>Results</h4>Plasma and CSF GFAP increased across the AD continuum, with higher levels in MCI and AD (p < 0.001).